NCE-1 Intelligence & Market Opportunity

Miplyffa

Arimoclomol

Neuroprotective

Oral Capsules

Miplyffa is used to treat Niemann-Pick disease type C. The combination of the drug Miplyffa and miglustat is suggested for the treatment of neurological symptoms of Niemann-Pick disease type C in adults as well as children who are at least two years old.

Approval Date

20-Sep-24

NCE-1 Date

20-Sep-28

NCE Date

20-Sep-29

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

0.4081

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

134

2027

213

2028

291

2029

342

2030

378

2031

418

2032

402

Molecule profile

Details & specifications

Molecule

Arimoclomol

Innovator

ZEVRA DENMARK AS

Dosage Form

Oral Capsules

Strength

47 mg, 62 mg, 93 mg and 124 mg

Therapeutic Category

Neuroprotective

Usage

To treat Niemann-Pick disease type C

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.